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Background: Patients with stage IV lung adenocarcinoma and
epidermal growth factor receptor (EGFR) mutation derive clinical
benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs).
Whether treatment with TKI improves outcomes in patients with
resected lung adenocarcinoma and EGFR mutation is unknown.
Methods: Data were analyzed from a surgical database of patients
with resected lung adenocarcinoma harboring EGFR exon 19 or 21
mutations. In a multivariate analysis, we evaluated the impact of
treatment with adjuvant TKI.
Results: The cohort consists of 167 patients with completely re-
sected stages I to III lung adenocarcinoma. Ninety-three patients
(56%) had exon 19 del, 74 patients (44%) had exon 21 mutations,
and 56 patients (33%) received perioperative TKI. In a multivariate
analysis controlling for sex, stage, type of surgery, and adjuvant
platinum chemotherapy, the 2-year disease-free survival (DFS) was
89% for patients treated with adjuvant TKI compared with 72% in
control group (hazard ratio  0.53; 95% confidence interval: 0.28–
1.03; p  0.06). The 2-year overall survival was 96% with adjuvant
EGFR TKI and 90% in the group that did not receive TKI (hazard
ratio: 0.62; 95% confidence interval: 0.26–1.51; p  0.296).
Conclusions: Compared with patients who did not receive adjuvant
TKI, we observed a trend toward improvement in DFS among individ-
uals with resected stages I to III lung adenocarcinomas harboring
mutations in EGFR exon 19 or 21 who received these agents as
adjuvant therapy. Based on these data, 320 patients are needed for a
randomized trial to prospectively validate this DFS benefit.
Key Words: Adjuvant therapy, Erlotinib, Gefitinib, EGFR muta-
tion, Lung adenocarinoma.
(J Thorac Oncol. 2011;6: 569–575)
The most effective treatment for lung adenocarcinoma iscomplete (R0) surgical resection, with anatomical resec-
tion (lobectomy or pneumonectomy) as the preferred surgical
procedure.1 Nevertheless, even for patients who have com-
plete resections, many are not cured, and rates of death 5
years after resection vary from 30% in stage IA to 75% in
stage IIIA.2 Perioperative cisplatin-based chemotherapy
given before and/or after surgery can increase overall survival
(OS) after non-small cell lung cancer (NSCLC) resection by
treating occult metastatic disease.3–6 Perioperative cytotoxic
chemotherapy reduces the risk of death at 5 years by approx-
imately 15% (absolute risk reduction) in patients with stage
IIIA disease and approximately 4% for patients with stage IB
NSCLC. For stage IA disease, despite the unacceptably high
recurrence rate at 5 years, treatment with adjuvant cisplatin
chemotherapy has no survival benefit.7
NSCLC is a heterogeneous disease, with activating
mutations in epidermal growth factor receptor (EGFR) play-
ing a key role in the growth and proliferation of approxi-
mately 20% of lung adenocarcinomas. Multiple prospective
trials demonstrate that individuals with advanced lung ade-
nocarcinomas that harbor EGFR mutations, deletions in exon
19, or L858R missense mutations at exon 21 experience a
high rate of radiologic response with the EGFR tyrosine
kinase inhibitors (TKIs) erlotinib (Tarceva) or gefitinib
(Iressa).8–11 Three randomized phase 3 trials demonstrated
that gefitinib is superior to platinum-based chemotherapy as
an initial treatment for advanced lung adenocarcinoma among
patients with EGFR mutations, improving both radiologic
response and progression-free survival.12–14 The presence of
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EGFR mutations may be an independent, good prognostic
factor in lung adenocarcinoma irrespective of therapy.12,15–17
Because EGFR TKIs are superior to cytotoxic drugs in
patients with advanced lung adenocarcinoma and EGFR mu-
tation, many have proposed that EGFR TKIs may also prove
advantageous when used as adjuvant treatments in this pop-
ulation. As such, our institution routinely tests all resected
lung adenocarcinomas for the presence of EGFR mutations.
This has allowed our participation in ongoing, prospective
clinical trials of EGFR TKIs for patients with EGFR muta-
tions (NCT00567359). It also affords the opportunity to
observe the clinical outcome of patients who received adju-
vant EGFR TKIs outside of a clinical trial. To accomplish
this, we reviewed a prospectively maintained surgical data-
base that includes clinical and molecular characteristics and
outcome data for patients with resected stages I to III lung
adenocarcinoma with EGFR mutations.
PATIENTS AND METHODS
Patients
In an institutional review board-approved surgical data-
base, we identified all patients with completely resected stages I
to III lung adenocarcinomas with EGFR mutations who had a
resection at Memorial Sloan-Kettering Cancer Center (MSKCC)
between May 2002 and August 2008. Some of these patients
received EGFR TKIs gefitinib or erlotinib pre and/or postoper-
atively as routine care or under the auspices of a clinical trial of
perioperative gefitinib.18 The surgical database prospectively
captures patient sex, age, type of surgery, histology, pathologic
stage, perioperative chemotherapy, and radiation. From the med-
ical record, we obtained the information regarding erlotinib or
gefitinib delivery, disease status, and survival. This review of
records was done under a waiver of authorization approved by
the MSKCC Institutional Review Board and Privacy Board.
According to the consensus of MSKCC surgeons and medical
oncologists, patients at MSKCC are followed up for disease
recurrence in uniform fashion, including a doctor visit and
computed tomography scan of the chest (preferably with IV
contrast) every 6 months until the 2-year anniversary of the date
of surgery and noncontrast computed tomography annually
thereafter.
EGFR Mutation Testing
Since January 2006, EGFR mutation testing has been
performed reflexively (automatically) at MSKCC by the mo-
lecular diagnostic core laboratory of the Department of Pa-
thology on all resected lung adenocarcinomas. DNA is ex-
tracted from formalin-fixed, paraffin-embedded tumor tissue
and tested by a polymerase chain reaction-based assays for
the two predominant types of EGFR mutations—short in-
frame deletions in exon 19 and a specific point mutation in
exon 21 at codon 858 (L858R) (methods described in Ref.
19). Before 2006, mutation testing was done on many, al-
though not all resected patients using a variety of techniques,
including direct sequencing. Using direct sequencing, tumors
from two patients were found to have a point mutation in
exon 21 at codon 861 (L861Q), which is also associated with
sensitivity to erlotinib and gefitinib.20–22
Statistical Analysis
The characteristics of patients who received neoadju-
vant and/or adjuvant TKI were summarized and compared
with the group that did not receive TKI using Wilcoxon rank
sum test or Fisher’s exact test. Disease-free survival (DFS)
was measured from date of surgery to date of recurrence or
death. OS time was measured from date of surgery to date of
death. Living patients were censored at the date of last contact.
Survival data were obtained using the medical record and the
Social Security Death Index. Survival status was updated in
March 2010. Survival probabilities were calculated by the
Kaplan-Meier method and compared among different groups
using the log-rank test. Univariate and multivariate Cox regres-
sion analyses were performed controlling for sex, stage, surgical
procedure, and perioperative platinum-based chemotherapy.
Perioperative erlotinib or gefitinib therapy was treated as a
time-dependent factor, so that when it was given after the
surgery, its effect would not be taken into account until the start
of the therapy. Statistical analyses were done using SAS (SAS
Institute, Inc., Cary, NC) software.
RESULTS
Patient Characteristics
We identified 167 patients with stages I to III com-
pletely resected lung adenocarcinomas harboring EGFR exon
19 or 21 mutations that underwent resection at MSKCC
between May 2002 and August 2008. The demographic
characteristics of the patients are summarized in Table 1. The
cohort consists predominantly (70%) of stage I resected lung
adenocarcinomas, such that only 47 patients (28%) in the
TABLE 1. Patient Demographic and Baseline Characteristics
Characteristics
Adjuvant
Erlotinib/
Gefitinib
(N  56)
No Adjuvant
Erlotinib/
Gefitinib
(N  111) p
Age (yr)
Median 66 70 0.050a
Range 37–88 35–89
Sex, no. (%)b
Male 15 (27) 31 (28) 1.00
Female 41 (73) 80 (72)
Pathologic stage, no. (%)
I 30 (54) 87 (78) 0.002
II 11 (20) 14 (13)
III 15 (27) 10 (9)
Cisplatin chemotherapy, no. (%) 22 (39) 23 (21) 0.016
Surgery type, no. (%)
Bilobectomy 3 (5) 0 0.010
Lobectomy 49 (88) 91 (82)
Pneumonectomy 1 (2) 0
Segmentectomy 1 (2) 9 (8)
Wedge 2 (4) 11 (10)
a p value calculated using Wilcoxon rank sum test. Other p values calculated using
Fisher’s exact test.
b Percentages may not sum to 100 because of rounding.
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entire cohort received perioperative cisplatin-based chemo-
therapy. Fifty-six patients (33%) received perioperative erlo-
tinib or gefitinib. The adjuvant erlotinib/gefitinib group had a
higher proportion of stage III patients. Stage distribution
among the group is summarized in Table 1. Twenty-one of
the adjuvant TKI-treated patients captured by the database
were enrolled in a phase 2 clinical trial and received periop-
erative gefitinib consisting of induction therapy for 21 days
before surgery and again postoperatively for up to 2 years.18
The remaining 35 patients received postoperative erlotinib or
gefitinib at the discretion of their physicians. The median
time between start of erlotinib/gefitinib therapy and surgery
was 2 months. The median time on erlotinib or gefitinib was
20 months (range, 0.3–51 months).
Survival Analysis
To date, a total of 46 recurrences (27%) and 29 deaths
(17%) have occurred. Ten patients died without documented
disease recurrence. Table 2 summarizes the characteristics of
patients who recurred or died. Of the patients who recurred,
43 developed unresectable metastatic disease: eight brain/
leptomeninges only, 15 lung/pleura only, and 20 recurrences
in multiple disease sites: brain, bone, lung, liver, or lymph
nodes. Three patients were rendered free of disease recur-
rence in the lung with surgery. These tumors were all his-
topathologically similar to the primary resection specimens
with identical EGFR mutations, excluding a second primary
lung tumor as a possibility.
In the entire cohort of completely resected stages I to III
lung adenocarcinoma harboring EGFR mutations, the median
OS and DFS of all patients were 76 months (95% confidence
interval [CI]: 71 to not reached) and 46 months (95% CI:
40–67), respectively. Kaplan-Meier survival estimates are
provided in Figure 1. In a multivariate analysis, after adjust-
ing for sex, pathologic stage, surgery type, and application of
cisplatin-based chemotherapy, patients treated with perioper-
ative erlotinib/gefitinib therapy had a 2-year DFS rate of 89%
compared with 72% for patients who were not treated with
perioperative erlotinib/gefitinib (p  0.06), presented in Ta-
ble 3. Of the 46 patients who experienced disease recurrence,
32 (69%) received EGFR TKI therapy for recurrent disease,
one patient was rendered disease free with resection and is
being monitored off therapy, three patients died without
FIGURE 1. Kaplan-Meier curves for survival. Kaplan-Meier curves for disease-free survival (panel A) and for overall survival
(panel B) by gefitinib/erlotinib therapy. G/E denotes gefitinib/erlotinib. *Hazard ratios were calculated with the use of a Cox
proportional hazards model, with the type of surgery, stage, cisplatin chemotherapy, and sex as covariates and gefitinib/erlo-
tinib therapy as time-dependent factor; Cox proportional hazards model with gefitinib/erlotinib therapy as time-dependent
factor. With respect to the disease-free survival and overall survival, results of a log-rank test, p  0.122 (panel A) and p 
0.912 (panel B).
TABLE 2. Characteristics of Patients Who Recurred or Died
Characteristics
Adjuvant
Erlotinib/Gefitinib
(N  13)
No Adjuvant
Erlotinib/Gefitinib
(N  43)
Age (yr)
Median 62 68
Range 38–88 35–85
Sex, no. (%)a
Male 6 (46) 13 (30)
Female 7 (54) 30 (70)
Pathologic stage, no. (%)
I 3 (23) 30 (70)
II 4 (31) 5 (12)
III 6 (46) 8 (19)
Cisplatin chemotherapy, no. (%) 7 (54) 10 (23)
a Percentages may not sum to 100 because of rounding.
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receiving erlotinib or gefitinib, and for 10 patients, the ther-
apy for metastatic disease is unknown. In a multivariate
analysis, patients treated with perioperative erlotinib/gefitinib
had a 2-year OS of 96% compared with 90% for patients who
were not treated with perioperative erlotinib/gefitinib (p 
0.296), presented in Table 4.
DISCUSSION
In advanced lung adenocarcinoma, the response rates to
EGFR TKI therapy in patients with EGFR mutations range
from 58 to 75% in prospective trials.9–12,15,23–25 Three ran-
domized phase 3 studies have demonstrated that EGFR TKI
therapy is superior to chemotherapy in this unique subset of
patients with advanced NSCLC.12–14 If we assume that pa-
tients with micrometastatic disease after surgery would have
a similar benefit, we can hypothesize that adjuvant EGFR
TKI could delay relapse or potentially cure patients with
resectable cancer who would otherwise relapse with adjuvant
cisplatin-based chemotherapy alone. In addition to being
potentially more effective than adjuvant cisplatin-based che-
motherapy in EGFR mutation-positive patients, EGFR TKIs
have fewer side effects making them an appealing treatment
option for patients with stage IA NSCLC, a subgroup for
which no adjuvant therapy currently exists.7
An important example of molecularly targeted adjuvant
therapy for patients with resected solid tumors is imatinib
mesylate (Gleevec) therapy for patients with gastrointestinal
stromal tumors, which express KIT protein (CD117) by
immunohistochemistry.26–29 A 770 patient randomized, pla-
cebo-controlled phase 3 trial demonstrated an improvement
in DFS for the imatinib mesylate arm (hazard ratio: 0.35;
95% CI: 0.22–0.53, p  0.0001).28 To date, an improvement
in OS from adjuvant imatinib has not been established.
Studies are ongoing to determine whether the decision to
treat, or dose of imatinib, should vary based on the presence
of KIT gene mutations.
As for adjuvant use of EGFR TKI for patients with
resected EGFR mutant lung adenocarcinoma, there are no
randomized trials directing this therapy. A multicenter, sin-
gle-arm, phase 2 trial (NCT00567359) is underway at Mas-
sachusetts General Hospital, Massachusetts General Hospital
affiliated hospitals, and MSKCC, which will prospectively
enroll 100 patients with resected NSCLC and activating
mutations in EGFR to receive erlotinib 150 mg daily dose for
up to 2 years after completion of all standard adjuvant
chemotherapy and radiation therapy.30 Thirty-six patients
have been enrolled during a course of 2 years. Rash, fatigue,
and diarrhea were the most common grade 3 toxicities oc-
curring in 14, 3, and 6% of patients, respectively. Ten (28%)
patients were dose reduced to erlotinib 100 mg (n  6) and
50 mg (n  4) due to toxicities, and five (14%) have
withdrawn as a result of toxicity or patient preference.30 The
primary end point is DFS at 2 years. Because this is a
single-arm trial, the data for patients with resected stages I to
III NSCLC and EGFR mutation who do not receive EGFR
TKI being collected at MSKCC will serve as an important
historical comparator.
Two randomized trials of adjuvant EGFR TKI for
patients with resected NSCLC have been initiated, but neither
trial is enriched for patients with EGFR mutations. There is
consensus that the greatest benefit of EGFR TKI therapy
occurs in metastatic patients with EGFR mutations12 and that
there is growing concern that there may be harm to EGFR
wild type or KRAS mutant patients treated with erlotinib or
gefitinib.12 Any data from EGFR TKI trials that do not select
patients based on presence of EGFR mutations may be
misleading.
The phase 3 National Cancer Institute of Canada BR19
trial comparing adjuvant gefitinib versus placebo in patients
with completely resected NSCLC was initiated but closed
early for safety concerns after interim analysis of phase 3
S0023 trial showed that maintenance gefitinib was worse than
placebo in unselected patients with inoperable stage III
NSCLC.31 As a result, BR19 accrued 503 of planned 1160
patients with median duration of active study therapy for less
than 5 months. The study eligibility criteria did not mandate
TABLE 3. Multivariate Disease-Free Survival Analysis
n  167 N (Event N)
2-yr Survival
(95% CI)
Adjusted Hazard
Ratioa (95% CI) Adjusted p
Adjuvant erlotinib/gefitinib 56 (13) 89% (77–95) 0.53 (0.28–1.03) 0.06
No adjuvant erlotinib/gefitinib 111 (43) 72% (61–80)
a Adjusted for sex, type of surgery, stage, and adjuvant cisplatin chemotherapy; hazard ratio less than 1.00 indicates
improved survival.
CI, confidence interval.
TABLE 4. Multivariate Overall Survival Analysis
n  167 N (Event N)
2-yr Survival
(95% CI)
Adjusted Hazard
Ratioa (95% CI) Adjusted p
Adjuvant erlotinib/gefitinib 56 (8) 96% (85–99) 0.62 (0.26–1.51) 0.296
No adjuvant erlotinib/gefitinib 111 (21) 90% (82–95)
a Adjusted for sex, type of surgery, stage, and adjuvant cisplatin chemotherapy; hazard ratio less than 1.00 indicates
improved survival.
CI, confidence interval.
Janjigian et al. Journal of Thoracic Oncology • Volume 6, Number 3, March 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer572
selection of patients based on molecular or clinical charac-
teristics that correlate with sensitivity to gefitinib such as
adenocarcinoma histology, female gender, never smoking
status, or East Asian ethnicity.32,33 The majority of patients
enrolled in BR19 were former or current smokers and in-
cluded patients with squamous cell histology.34 Tissue sam-
ples from 357 of 503 patients who received treatment on
BR19 were studied with the goal of demonstrating a clinical
benefit for adjuvant gefitinib in the subgroup of patients with
EGFR mutations. Mutation status in 30% of patients treated
on BR19 remains unknown. Because the BR19 patient pop-
ulation was not enriched for presence of EGFR mutations and
mutation testing was limited to a subgroup of patients, only
76 patients with EGFR mutations (40 in the placebo arm and
36 in the gefitinib arm) were included in the study.34 The
incidence for grade 3 or 4 adverse events was very low, with
dyspnea being the most common serious adverse event and
equally balanced between gefitinib and placebo arms seen in
5% of patients in each treatment arm. A higher incidence of
pneumonitis was noted in the placebo arm. In an exploratory
analysis in a subset of patients with EGFR mutations, ge-
fitinib therapy did not result in disease free or OS benefit.34
Taking into account that this was a subgroup analysis of an
underpowered study that was terminated early with some
patients receiving only a few days of study therapy, the
results of BR19 cannot be used to draw conclusions about the
impact of adjuvant EGFR TKIs in patients with lung adeno-
carcinoma and EGFR mutation.
The Randomized Double-Blind Trial In Adjuvant
NSCLC with Tarceva (RADIANT) is another phase 3 trial
that is currently investigating adjuvant erlotinib therapy in
patients with resected NSCLC who have overexpression of
EGFR protein by immunohistochemistry or EGFR gene am-
plification by fluorescence in situ hybridization. Although
EGFR mutations are not a prerequisite for the RADIANT
study entry, EGFR mutation analysis was performed on
tumors from 278 patients enrolled to date. As expected, the
rate of EGFR exon 19 and 21 mutations in this unselected
patient population is 12%.35 The planned accrual for the
RADIANT trial is 945 patients, which will result in approx-
imately 113 patients (approximately 60 patients per treatment
arm) with tumors that harbor EGFR mutation. Again, based
on our data, it is unlikely that a significant difference in
outcomes can be demonstrated in this number of patients.
Subdividing the data into subgroups reduces the study’s
power to detect treatment differences by reducing the sample
size and increasing the number of statistical tests needed to
test for an interaction between different clinical factors.36
In contrast to the RADIANT and BR19 trials, our
cohort consists exclusively of patients with resected lung
adenocarcinomas with EGFR mutations. The majority of
molecular testing on our patients was performed prospec-
tively, and all testing was done at a single laboratory. In
regard to surgery and chemotherapy, the majority of the
patients in this cohort had uniform management for their lung
adenocarcinoma by the MSKCC Thoracic Disease Manage-
ment Team.
Although the large number of patients from a single
institution makes this data important, there are limitations to
our analysis. Treatment with adjuvant erlotinib/gefitinib was
largely dependent on the patients’ and their oncologists’
preference. Seventy percent of patients who received the
EGFR TKI had stages I and II disease, and given the long
natural history of early stage EGFR mutant lung adenocarci-
noma, the 2-year DFS may be too short to adequately reflect
the population outcome. Patients with more advanced tumors
were more likely to be offered, or motivated, to take adjuvant
TKI therapy as an innovative therapy after surgery and
completion of standard adjuvant therapy. Because more high-
risk patients were treated with adjuvant TKI, this would tend
to bias the results against the therapeutic impact of the TKI.
We accounted for differences in prognostic variables between
patients who did and did not receive adjuvant TKI by adjust-
ing for age, sex, and pathologic stage through a multivariate
analysis. A proportion of patients received gefitinib therapy
preoperative and postoperatively, whereas others only re-
ceived erlotinib postoperatively. Finally, we did not control
for the doses or duration of EGFR TKI therapy, and we did
not collect toxicity data prospectively, although no patient
was identified whose death was attributed to treatment with
erlotinib or gefitinib.
Despite the study limitations, we have demonstrated for
the first time that adjuvant therapy with erlotinib or gefitinib
in patients with resected lung adenocarcinoma harboring
EGFR mutations may have an impact on DFS (hazard ratio
0.53, 95% CI: 0.28–1.03, p  0.06). Given the potential
magnitude of DFS benefit our data support, and the relatively
small number of patients needed in a randomized trial to
confirm these observations, a phase 3 trial is justified. The
primary end point should be DFS, the same end point that
was used in the trial that lead to the approval of imatinib in
patients with KIT-positive gastrointestinal stromal tu-
mors.26,27 OS cannot be used as the primary end point
because virtually all patients with recurrent lung adenocarci-
noma and EGFR mutation will receive an EGFR TKI at
recurrence. Based on our results, the number of EGFR mu-
tation-positive lung adenocarcinoma cases in RADIANT (es-
timate n  120), BR19 (n  76), and the ongoing single-arm
NCT00567359 trial (n  100) pooled together will be insuf-
ficient to prove a clinically significant DFS advantage of
adjuvant EGFR TKI therapy. Appropriate patient selection
with deliberate trial design and sample size justification will
be essential to demonstrate the survival benefit for adjuvant
therapy in a resected lung adenocarcinoma population that
may have a favorable prognosis irrespective of therapy.
This analysis was performed to provide the framework
for further investigation of adjuvant EGFR TKI therapy in
patients with lung adenocarcinoma with EGFRmutations. On
the basis of this data, we propose a phase 3 study to detect a
47% reduction in the risk of lung cancer recurrence or death.
To demonstrate this improvement in DFS, 320 patients would
be needed, with 160 patients per treatment arm, during a
3-year accrual time, and 2-year follow-up (trial design pro-
posed in Figure 2). This design provides 85% power at 5%
type I error rate. There is a theoretical possibility that adju-
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vant TKI might improve DFS, but injure patients or breed-
resistant clones, which, in the long run, might result in worse
OS. As such, we propose that the validation protocol will
measure OS and mandate that enrolled patients with recurrent
cancer must be treated with first-line TKI at recurrence, thus
allowing a comparison of radiologic response rate and pro-
gression-free survival between the two arms of the study at
recurrence giving early insight into the potential problem of
acquired resistance to EGFR TKIs, which may develop from
adjuvant TKI therapy.
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